Archive

Treatment-Induced Neuropathy Presenting as Thoracic Radiculopathy and Abdominal Wall Protrusion After Marked Glycemic Improvement With Tirzepatide

HbA1c fell from 11.0% to 6.6% over seven months with 17-pound weight loss; weeks later he developed severe thoracoabdominal neuropathic pain and abdominal wall weakness.

Endocrinology · Cureus · 29 Sept

Associations Among Glycemic Variability, Hypomagnesemia, Thyroid Function, and Albuminuria in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study

Beyond HbA1c, visit-to-visit glucose swings and low magnesium tracked with albuminuria in T2DM, suggesting both as cheap add-on risk markers in Indian clinics.

Endocrinology · Cureus · 29 Sept

Association of the Triglyceride–Glucose Index with Systolic and Diastolic Blood Pressure Among Patients With Type 2 Diabetes Mellitus

A cheap index from routine fasting lipids and glucose may flag T2DM patients heading for hypertension, so you can intensify BP surveillance without extra tests.

Endocrinology · Cureus · 29 Sept

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

Triple GIP/GLP-1/glucagon agonism adds another injectable option for patients with obesity and type 2 diabetes who fail current GLP-1 therapy.

Endocrinology · Lancet · 29 Sept

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

A triple GIP/GLP-1/glucagon agonist given weekly for 80 weeks produced substantial weight loss in adults with obesity without diabetes, adding a third incretin option beyond current dual agonists.

Endocrinology · NEJM · 29 Sept

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

An oral GLP-1 agonist taken without fasting or diet rules could offer injection-free glycaemic control for early type 2 diabetes, pending full efficacy and safety data.

Endocrinology · Nature Medicine · 29 Sept

FDA Approves First Treatment for MCT8 Deficiency

First approved therapy for this rare X-linked thyroid hormone transport defect; tiratricol lowers peripheral thyrotoxicosis, so paediatricians and endocrinologists can now offer disease-directed treatment rather than supportive care.

Endocrinology · FDA — Press Announcements · 29 Sept

Association of Serum Magnesium Concentration With Microvascular Complications Among Patients Diagnosed With Type 2 Diabetes Mellitus: An Observational Cross-Sectional Analysis

Low serum magnesium tracked with retinopathy, nephropathy and neuropathy in T2DM patients; consider checking magnesium in poorly controlled diabetes rather than ignoring it.

Endocrinology · Cureus · 28 Sept

Systemic Glucose-Lowering Therapies and Periodontal and Peri-Implant Outcomes in Adults With Type 2 Diabetes Mellitus: A Systematic Review

Evidence on whether SGLT2 inhibitors and other glucose-lowering classes improve periodontal and peri-implant outcomes in your T2DM patients remains sparse, so current choices rest on glycaemic control alone.

Endocrinology · Cureus · 27 Sept

Glycemic Dynamics and Management Strategies in Individuals With Type 1 Diabetes During Ramadan: A Continuous Glucose Monitoring-Based Narrative Review

Glycaemic outcomes were heterogeneous, ranging from deterioration to temporary improvement or stability. Hypoglycaemia exposure did not appear to increase; postprandial hyperglycaemia clustered around the evening and pre-dawn meals was the predominant and most variable challenge.

Endocrinology · Cureus · 26 Sept

IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis

A weekly insulin-semaglutide combo may cut injections while limiting insulin-related weight gain and hypoglycaemia, but heterogeneous comparators mean efficacy estimates remain uncertain.

Endocrinology · Cureus · 25 Sept

Berry Street, Abbott partner to link Lingo CGM with nutrition coaching

Pairing an OTC CGM with dietitian coaching may improve glycaemic control in prediabetes and obesity, but outcome data are still lacking.

Endocrinology · Fierce Healthcare · 23 Sept

Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System

GLP-1 users may report muscle and joint events; ask about myalgia and lean-mass loss at follow-up, especially in older patients on tirzepatide.

Endocrinology · Cureus · 23 Sept

CD10-Positive Extranodal Marginal Zone Lymphoma of the Thyroid Arising in Hashimoto’s Thyroiditis: A Rare Diagnostic Challenge

In Hashimoto's patients with an FDG-avid thyroid nodule, consider marginal zone lymphoma and biopsy rather than assuming benign thyroiditis.

Endocrinology · Cureus · 22 Sept

Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review

Evidence that tirzepatide may preserve β-cell function, not just lower glucose, could shift when you start dual GIP/GLP-1 therapy in T2DM.

Endocrinology · Cureus · 22 Sept

Parathyroid Storm Secondary to a Parathyroid Adenoma Presenting With Recurrent Generalised Tonic-Clonic Seizures and Refractory Hypercalcaemia: A Case Report

Refractory hypercalcaemia with seizures demands urgent parathyroidectomy, not just medical therapy; suspect parathyroid storm when calcium exceeds 4 mmol/L with neuropsychiatric decline.

Endocrinology · Cureus · 22 Sept

Autoimmune Conversion of Hashimoto’s Thyroiditis to Graves’ Disease With Immune Pancytopenia in a Patient With Seropositive Rheumatoid Arthritis: A Diagnostic and Therapeutic Conundrum

In RA patients with cytopenias, check thyroid autoimmunity before starting antithyroid drugs, since conversion to Graves' can make ATD therapy hazardous.

Endocrinology · Cureus · 22 Sept

Renin-Angiotensin System (RAS) Inhibitors in High-Risk Patients With Type 2 Diabetes and Cardio-Renal Risk

Despite clear guideline backing, many high-risk T2D patients with cardio-renal risk are not on RAS inhibitors — check your own CKD and albuminuria patients.

Endocrinology · Cureus · 22 Sept

Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes

Another dual GLP-1/GIP agonist reaching phase 2 endpoints expands the obesity-diabetes drug class your patients already ask about, though no head-to-head data yet.

Endocrinology · Fierce Biotech · 22 Sept

Association of Finerenone Dose and Estimated Glomerular Filtration Rate (eGFR) Slope Changes in Patients With Diabetic Kidney Disease: A Real-World Retrospective Study

Annual eGFR slope improved from -5.20 to +0.27 mL/min/1.73 m²/year (p = 0.0144). The 10 mg/day group improved from -7.11 to +3.35 (p = 0.00041); the 20 mg/day group did not (-3.29 to -2.85, p = 0.865).

Endocrinology · Cureus · 21 Sept

Severe Suspected Metformin-Associated Lactic Acidosis With Relatively Preserved Serum Creatinine at Presentation: Sequential Intermittent Hemodialysis and Continuous Venovenous Hemodialysis

Lactate was 24.1 mmol/L and peaked at 25.5 mmol/L, total CO2 <5 mmol/L, but creatinine only 1.18 mg/dL. Lactate declined from 25.5 to 16.0 mmol/L before dialysis; normalized after intermittent then continuous hemodialysis.

Endocrinology · Cureus · 21 Sept

Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice

A preclinical oral cannabinoid agonist matched semaglutide for weight loss in mice, but human data are years away and clinicians should not expect a near-term alternative.

Endocrinology · Fierce Biotech · 18 Sept

Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope

Three early-stage obesity candidates entering Novo's pipeline signal more oral or combination options may reach your patients within a few years.

Endocrinology · Fierce Biotech · 18 Sept

Iodine nutrition, thyroid function, and thyroid autoimmunity four decades after Universal Salt Iodisation in India: a cross-sectional study among schoolchildren (ICMR-SALT-T 1).

Four decades of salt iodisation may now be causing iodine excess and rising thyroid autoimmunity in Indian children, so consider this before attributing paediatric thyroid dysfunction to deficiency.

Endocrinology · Lancet regional health. Southeast Asia · 18 Sept

Prevalence and Severity of Hepatic Steatosis and Fibrosis Across Glycemic Categories Among Patients Attending a Tertiary Care Hospital: A FibroScan-Based Cross-Sectional Study

Severe steatosis (S3) in 2.4% nondiabetic, 6.9% prediabetic, 18.7% T2DM; adjusted aOR 2.22 (1.26-3.94) for prediabetes and 3.58 (1.58-8.14) for T2DM. Fibrosis distribution did not differ (p = 0.480).

Endocrinology · Cureus · 17 Sept

Abnormally Low Hemoglobin A1c Due to a Heterozygous Alpha-Globin Variant (Hb I; HBA2 c.49A>G, p.Lys17Glu) in a Geriatric Patient

A heterozygous HBA2 variant, Hb I, caused a profoundly low HbA1c with no clinical phenotype; heterozygotes are clinically silent, so the only consequence is assay interference.

Endocrinology · Cureus · 17 Sept

Myxoedema Coma With Type 2 Respiratory Failure and Hypothermia in an Oedematous Patient: A Case Report

Profound hypothyroidism confirmed (TSH 67 mU/L, T4 <2 pmol/L). She deteriorated with hypothermia, hypotension, bradypnea and reduced consciousness, requiring ICU and intubation, then improved on intravenous liothyronine and levothyroxine.

Endocrinology · Cureus · 16 Sept

Exacerbation of Pre-existing Hypothyroidism Following Enarodustat Administration in a Patient on Peritoneal Dialysis: A Case Report

If you prescribe enarodustat for renal anaemia, check thyroid function — it can worsen pre-existing hypothyroidism, as roxadustat does.

Endocrinology · Cureus · 16 Sept

Assessing the Growing Impact of Oral GLP-1 Agonists on National Obesity Policies of the United Kingdom

No original data. The authors discuss access inequalities and state provision of oral GLP-1 receptor agonists, and argue these drugs should augment, not replace, established weight-management methods.

Endocrinology · Cureus · 15 Sept

Prevalence of Mild Autonomous Cortisol Secretion Among Patients With Adrenal Incidentaloma and Its Association With Metabolic Abnormalities: A Hospital-Based, Analytical, Cross-Sectional Study

MACS in 95 (25.0%). Adjusted associations: obesity aOR 1.85 (1.09-3.14), diabetes aOR 1.68 (1.01-2.80), metabolic syndrome aOR 1.82 (1.11-2.98); lesion size aOR 1.38 per cm (1.14-1.67).

Endocrinology · Cureus · 15 Sept

Evaluation of Alterations in Serum Uric Acid Levels in Newly Diagnosed Overt Thyroid Dysfunction: A Prospective Observational Study From a Tertiary Care Center

Uric acid was higher in thyroid dysfunction than controls (5.62 ± 2.28 vs. 4.46 ± 1.13 mg/dL, p < 0.001); creatinine was lower (0.86 ± 0.16 vs. 0.92 ± 0.22 mg/dL, p = 0.010). Uric acid AUC 0.642, cutoff 4.05 mg/dL, 71.3% sensitivity.

Endocrinology · Cureus · 15 Sept

Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists

Liraglutide established GLP-1 agonism for weight management; semaglutide gave greater, more sustained weight reduction; tirzepatide produced greater weight loss than semaglutide in direct comparative studies.

Endocrinology · Cureus · 15 Sept

The Potential Therapeutic Effects of Testosterone on Sarcopenia: A Thorough Systematic Review

Testosterone may modestly improve muscle mass and strength in older adults with sarcopenia, but evidence on falls and function remains weak — counsel patients before prescribing.

Endocrinology · Cureus · 15 Sept

Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi

A peripherally restricted CB1 inverse agonist may deliver weight loss without the neuropsychiatric toxicity that ended earlier CB1 obesity programmes; phase 2 will test that claim.

Endocrinology · Fierce Biotech · 14 Sept

Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

SGLT2 inhibitors gave consistent heart failure and kidney benefit; GLP-1 receptor agonists gave strong atherosclerotic cardiovascular benefit and greater weight loss. Combination therapy looked complementary but was not proven superior to selected monotherapy.

Endocrinology · Cureus · 10 Sept

Interra Health now supports CMS’ GLP-1 Bridge Program

If you prescribe GLP-1s, this platform flags patients who may qualify for the CMS Bridge Program, easing access and cost barriers.

Endocrinology · Fierce Healthcare · 9 Sept

Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

A new Lilly-backed spinout with $50M may bring a next-gen diabetes option—watch for efficacy or safety gains over current therapies.

Endocrinology · Fierce Biotech · 9 Sept

Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

A new GLP-1 for obesity and diabetes is entering Europe; watch for pricing and supply competition that may affect your patients' access.

Endocrinology · Fierce Biotech · 4 Sept

Smoking raises death risk by 55% in people with diabetes, global experts call for active quit treatment

For your diabetic patients who smoke, actively offer cessation—this consensus quantifies a 55% higher death risk and urges routine intervention.

Endocrinology · ETHealthworld · 4 Sept

Vitamin D3 more effective than Vitamin D2 in maintaining muscle, heart health: ICMR-NIN study

Prefer D3 supplements for patients needing vitamin D, as D2 may inadequately protect muscle and cardiac structure.

Endocrinology · ETHealthworld · 2 Sept